Findings From a Prospective Phase II Study With Dostarlimab for Advanced Local Rectal Cancer

Findings From a Prospective Phase II Study With Dostarlimab for Advanced Local Rectal Cancer

header-info

In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response..